Funds are in risk off buying mode since the debt/shutdown decable/close on 3Q. Celldex is pure high potential independent biotech with multiple shots on goal this quarter. An envious position to be in, but risk still exists whilst we wait on the data for several drugs in the pipeline. Everyone is waiting on the next news cycle that will trigger the next (likely big) move. As a long and strong stakeholder, my money is on positive data/news coming in for our adjuvant to checkpoint inhibition (CDX-1127), Rindo + Avastin combination therapy for refractory glioblastoma, the complement inhibitor (CDX-1135) for ultra orphan indication of dense deposits disease AND (yes AND) start of accelerated phase III for (CDX-010) for breast cancer. I know it seems overly optimistic, but it's well within the realm of possibilty that most if not all of these come in positive before the end of this year! Most of us here think that despite the recent pps decline that you want to be in these shares ahead of these catalysts and buy more as they come in like ducks in a row. A huge run into next year is possible. An independent biotech with all this going for it is worth much more and the risk/reward is also much better here than most realize.
You said it grey. Nothing has changed other than fear in the market and when they say bios are out if favor for now they sell to protect profits. Doesn't matter about the potential for there products. They just SELL. Nothing has changed. NOTHING. We understand that